Every 10-Q that Jackson Acquisition Company II (JACS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JACS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JACS filings page.
Jackson Acquisition Company II is a Cayman Islands-based blank check company seeking a healthcare-focused Business Combination. As of June 30, 2026, it held $246,845,170 in a U.S. Treasury-backed Trust Account and total assets of $247,289,503, generating interest income but no operating revenue.
For the three and six months ended June 30, 2026, it reported net income of $1,980,048 and $3,949,131, driven by trust interest of $2,164,627 and $4,301,982, partially offset by general and administrative expenses. Public Class A shares are redeemable at $10.73 per share, with 23,000,000 shares classified as temporary equity.
The company reported cash outside the Trust of $358,338 and a working capital deficit of $132,101. Management disclosed that the need to complete a Business Combination by December 11, 2026 or liquidate, together with expected costs, raises substantial doubt about its ability to continue as a going concern. It also outlined NYSE listing risk after falling below the 300 public shareholder requirement, with a cure plan accepted through August 6, 2027.
Jackson Acquisition Company II, a healthcare-focused SPAC, reported net income of $1,969,083 for the quarter ended March 31, 2026, mainly from interest on marketable securities in its Trust Account. Interest income was $2,137,355, while general and administrative costs were $168,272.
The Trust Account held $244,680,543 invested in U.S. Treasury-focused money market funds, and cash outside the trust was $393,467 to fund ongoing search and operating costs. Management highlights substantial doubt about the company’s ability to continue as a going concern if no Business Combination is completed by December 11, 2026.
The company also discloses a NYSE notice received on February 6, 2026 for non-compliance with the 300 public shareholders requirement and has submitted a remediation plan. If compliance is not restored, its securities could be delisted, which could complicate completing a Business Combination.
Jackson Acquisition Company II filed its quarterly report, showing interest-driven profitability as it continues its SPAC search. The company reported net income of $2,346,020 for Q3 and $6,891,757 for the nine months ended September 30, 2025, primarily from $2,475,639 in Q3 interest earned on funds in its trust.
Assets in the Trust Account were $240,215,212 as of September 30, 2025, with $585,116 in cash held outside the trust and a working capital surplus of $307,890. Public Class A shares (23,000,000) remain recorded at redemption value, and the SPAC has until December 11, 2026 to complete a business combination. As of November 6, 2025, there were 23,840,000 Class A and 5,750,000 Class B ordinary shares outstanding. Management concluded disclosure controls were effective and noted sufficient liquidity for at least one year.
Jackson Acquisition Company II is a blank check company formed to complete a Business Combination with a focus on healthcare services and healthcare technology. As of June 30, 2025 the company held $237,739,573 in marketable securities in a Trust Account and $721,661 in cash outside the Trust Account. The company has 23,000,000 Class A ordinary shares subject to possible redemption, presented as temporary equity at their redemption value.
For the three months ended June 30, 2025 the company reported net income of $2,318,336 and for the six months ended June 30, 2025 net income of $4,545,737. These results were driven by interest earned on Trust Account investments ($2,447,373 for the quarter; $4,881,095 year-to-date), partially offset by general and administrative expenses ($129,037 quarter; $335,358 six months). Net cash used in operating activities for the six months was $227,705, and management states available funds support working capital for at least one year. The company has not commenced operations and must complete a Business Combination within a 24-month Combination Period following its IPO.